Date published:
Media type:
Statement
Audience:
General public
Australia’s health leaders are increasingly concerned about the growing availability, promotion and use of unapproved peptide products in Australia.
Reports received by the Therapeutic Goods Administration (TGA), along with hospitalisation data from states and territories, have identified serious adverse effects associated with the use of unapproved peptides. These include:
- liver damage
- severe allergic reactions requiring hospitalisation, and
- inflammation and other health complications requiring medical attention.
Unapproved peptide products that are not included in the Australian Register of Therapeutic Goods have not been evaluated by the TGA for safety, quality or effectiveness. These can include products containing BPC‑157, GHK‑Cu, TB‑500, retatrutide and CJC‑1295.
Read the full joint statement on the TGA website
Contact
Departmental media enquiries
Contact for members of the media.